Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 265

Results For "Men"

10176 News Found

Sanofi Consumer Healthcare India reports robust Q4 and FY’25 growth
News | February 26, 2026

Sanofi Consumer Healthcare India reports robust Q4 and FY’25 growth

For the fourth quarter, revenue surged 47% year-on-year to Rs. 2,510 million, driven by a 23% rise in domestic sales and a 9.3x jump in export sales


Volta Labs unveils push-button PCR-free whole genome sequencing kit
News | February 26, 2026

Volta Labs unveils push-button PCR-free whole genome sequencing kit

The new solution combines Watchmaker Genomics’ high-performance NGS chemistry with Volta’s digital fluidics platform


Gilead to acquire Arcellx in $7.8 billion bet on next-generation CAR T therapy
Biotech | February 26, 2026

Gilead to acquire Arcellx in $7.8 billion bet on next-generation CAR T therapy

Arcellx develops innovative immunotherapies for cancer and other incurable diseases


Asahi Kasei to acquire German biopharmaceutical company Aicuris for €780 million
News | February 26, 2026

Asahi Kasei to acquire German biopharmaceutical company Aicuris for €780 million

Asahi Kasei is consistently pursuing its strategy of building a focused, sustainable specialty pharmaceutical platform for immunocompromised and medically complex patient groups


Alembic announces USFDA final approval for Efinaconazole Topical Solution, 10%
Drug Approval | February 25, 2026

Alembic announces USFDA final approval for Efinaconazole Topical Solution, 10%

Efinaconazole Topical Solution is indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes.


Indoco Remedies receives final ANDA approval from USFDA for Brivaracetam Oral Solution, 10 mg/mL
Drug Approval | February 25, 2026

Indoco Remedies receives final ANDA approval from USFDA for Brivaracetam Oral Solution, 10 mg/mL

Brivaracetam Oral Solution (10 mg/mL) is a prescription antiepileptic drug (anticonvulsant) used for treatment of partial-onset seizures in patients 1 month of age and older


Shilpa Biologicals and SteinCares ink strategic pact to bring biosimilars to Latin America
News | February 25, 2026

Shilpa Biologicals and SteinCares ink strategic pact to bring biosimilars to Latin America

New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform


BNB Plus’ Biopharma subsidiary LineaRx lands major LineaDNA orders
News | February 25, 2026

BNB Plus’ Biopharma subsidiary LineaRx lands major LineaDNA orders

The announcement follows a record-setting $1.2 million accelerated LineaDNA order


CStone Pharmaceuticals’ Sugemalimab bags UK nods for Stage III NSCLC
Clinical Trials | February 25, 2026

CStone Pharmaceuticals’ Sugemalimab bags UK nods for Stage III NSCLC

Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity


Formosa strikes exclusive deal with Arrotex to launch eye surgery drug in Australia & NZ
News | February 25, 2026

Formosa strikes exclusive deal with Arrotex to launch eye surgery drug in Australia & NZ

The innovative eyedrop targets inflammation and pain following ocular surgery